Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its position in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 4.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 956,574 shares of the company's stock after acquiring an additional 39,831 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.65% of Adaptive Biotechnologies worth $5,735,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. KBC Group NV acquired a new position in shares of Adaptive Biotechnologies during the fourth quarter worth $50,000. Townsquare Capital LLC bought a new stake in Adaptive Biotechnologies during the third quarter valued at $56,000. GAMMA Investing LLC acquired a new position in shares of Adaptive Biotechnologies in the 4th quarter valued at about $59,000. Centiva Capital LP bought a new position in shares of Adaptive Biotechnologies during the 3rd quarter worth approximately $80,000. Finally, Proficio Capital Partners LLC acquired a new position in shares of Adaptive Biotechnologies during the 4th quarter valued at $93,000. Institutional investors own 99.17% of the company's stock.

Analyst Upgrades and Downgrades

ADPT has been the topic of several research reports. Scotiabank upped their price objective on shares of Adaptive Biotechnologies from $10.00 to $12.00 and gave the stock a "sector outperform" rating in a report on Thursday, February 13th. Piper Sandler reiterated an "overweight" rating and set a $11.00 target price (up from $7.00) on shares of Adaptive Biotechnologies in a research note on Thursday, February 20th. The Goldman Sachs Group raised Adaptive Biotechnologies from a "neutral" rating to a "buy" rating and increased their price objective for the company from $8.00 to $9.00 in a report on Friday, March 21st. Finally, BTIG Research boosted their price target on shares of Adaptive Biotechnologies from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Wednesday, December 18th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Adaptive Biotechnologies has an average rating of "Buy" and a consensus price target of $9.40.

Remove Ads

Adaptive Biotechnologies Stock Down 6.7 %

Shares of ADPT traded down $0.55 during trading hours on Friday, reaching $7.67. 1,563,957 shares of the company traded hands, compared to its average volume of 1,474,527. Adaptive Biotechnologies Co. has a 12 month low of $2.28 and a 12 month high of $9.01. The company's fifty day moving average price is $7.88 and its two-hundred day moving average price is $6.33. The company has a market capitalization of $1.14 billion, a price-to-earnings ratio of -7.04 and a beta of 1.53.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last released its earnings results on Tuesday, February 11th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.04. Adaptive Biotechnologies had a negative net margin of 89.12% and a negative return on equity of 64.65%. During the same period in the prior year, the firm posted ($0.30) EPS. On average, analysts expect that Adaptive Biotechnologies Co. will post -0.92 EPS for the current year.

Insider Buying and Selling

In other news, insider Francis Lo sold 20,875 shares of Adaptive Biotechnologies stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $6.99, for a total value of $145,916.25. Following the completion of the transaction, the insider now owns 332,846 shares in the company, valued at approximately $2,326,593.54. The trade was a 5.90 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert Hershberg sold 53,000 shares of the firm's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $7.59, for a total transaction of $402,270.00. Following the completion of the sale, the director now owns 69,690 shares of the company's stock, valued at $528,947.10. This trade represents a 43.20 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 757,601 shares of company stock valued at $6,040,624. 6.20% of the stock is owned by insiders.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.